Medizone International — Corporate Update (September 2017)
14 slides from Medizone International's corporate update, Sep 19, 2017
Slide 1: AsepticSure Medizone International Investor Update
AsepticSure® Medizone International, Inc.Investor Update – September 18, 2017 1 September 18, 2017 – 10:00 – 10:30 AM ESTToll free for North America: 1-800-681-1924Toll call outside North America: 1-303-223-4393A recording of the call will be available from 9/18/17-9/25/17:1-800-633-8284 Conference
Slide 2: Safe Harbor Statement
Safe Harbor Statement This investor update contains forward looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a
Slide 3: Agenda
Agenda Leadership TransitionCompany overviewThe Problem – The SolutionRegulatory updateFinancialsQuestion & AnswerClosing comments 3 Investor Update 9/18/17
Slide 4: Leadership Transition
Leadership Transition David A. Dodd has been appointed to the position of Chief Executive Officer and a member of the Board of DirectorsDavid A. Esposito will remain the Chairman of the Board 4 Investor Update 9/18/17
Slide 5: David A. Dodd – Transformational Leadership Experience & Success
Investor Update 9/18/17 5 David A. DoddTransformational Leadership Experience & Success Successful experience in achieving multi-billion dollar value-transformations in Pharma & BiotechBig pharma (BMS, Divisional GM; Wyeth, US Pharma Head)Mid pharma (Solvay, CEO)Development-stage pharma (Aeterna Zen
Slide 6: Company Overview - Executive Summary
Company Overview - Executive Summary Medizone International (OTCQB:MZEI) Company formed in 1986 to develop treatments for lipid enveloped virus like Hepatitis B & C and HIV/AIDSStrategic shift in 2007 to develop a disinfectant system capable of addressing a wide range of applications to minimize the
Slide 7: The Challenge & Problem
The Challenge & Problem Reducing the transmission of disease remains a global health priority 7 1. 2005 - California Air Resources Board’s “Indoor Air Pollution Report” and 2008 Independent studies by AMA, EPA, and CDC Healthcare facilities110% of inpatients contract infections in a hospital room th
Slide 8: Current technologies have limited impact
Standard cleaningTime consuming, labor intensive and costlyProven ineffective and inconsistent Current technologies have limited impact 8 UV TechnologyShadow effect impacts efficacyLack of regulatory approved efficacy claims Ozone TechnologyHigh levels (500+ PPM) needed to achieve necessary kill rat
Slide 9: The Solution - The AsepticSure System
9 The Solution - The AsepticSure System Ease of use in a wide range of applications The Science of Synergy EPA validated disinfectant process: AsepticSure produced consistent kill rates across 160 runs using a nominal 1.4% Hydrogen peroxide mixture combined with 80 ppm of OzonePeer reviewed/publishe
Slide 10: Compelling Scientific Evidence; Worldwide addressable markets
Compelling Scientific Evidence Worldwide addressable marketsHealthcare facilities (human and veterinary) Death care industry: mortuary preparation areas Athletic equipment and facilities Bioterrorism countermeasures Public health preparedness Building remediationPesticide (chemical) free disinfectio
Slide 11: Regulatory Progress - FDA Communications
513(g) submission made on May 17, 2017 FDA response to 513 (g)Written response received in late August (press release on 8/25)Follow-up teleconference held on Sept 7th The Company is preparing a 510k submissionFile a a pre-submission packet for a 510K submissionSchedule an in person meeting with FDA
Slide 12: Financials
Prior budgets supported through sales and exempt private placements of equitySecure Near Term FinancingRecently closed a $500,000 private equity offeringPotential to open another private equity offeringPreferred stock offering with strategic partnersEMA Partners outreach: Focused on securing a devel
Slide 13: Agenda
Agenda Leadership TransitionCompany overviewThe Problem – The SolutionRegulatory updateFinancialsQuestion & AnswerClosing comments 13 Investor Update 9/18/17
Slide 14: Summary and Closing Comments
Investor Update 9/18/17 14 Summary and Closing Comments Reducing the transmission of disease remains a global health priorityAsepticSure is well positioned to be a superior solution worldwide within healthcare, biodefense, and public health functionsMedizone is continuing to expand the commercial ca
Medizone International — Corporate Update (September 2017) on 6ix